New Haven Pharmaceuticals
Latest round
- Series B
Last raised
- Oct 2014
Total raised
- $18M
Investors
- 4
About New Haven Pharmaceuticals
New Haven Pharmaceuticals Inc.New Haven Pharmaceuticals Inc. is focused on the development of prescription drugs utilizing well-established drugs and Generally Recognized As Safe (GRAS) active pharmaceutical ingredients. The company operates from Guilford, US.79 mn.New Haven Pharmaceuticals specializes in the development of prescription drugs that utilize well-established drugs and GRAS (Generally Recognized as Safe) active pharmaceutical ingredients. Their core product offerings focus on innovative drug formulations that leverage the safety profiles of known compounds, addressing various unmet medical needs across therapeutic areas. These products are designed for healthcare providers and patients seeking effective treatments with reduced regulatory barriers, ultimately enhancing patient care. The company aims to improve access to advanced medical therapies and targets markets within the United States and Europe, ensuring that its offerings reach a broad range of healthcare settings.New Haven Pharmaceuticals generates revenue through a structured approach that includes partnerships with healthcare providers, pharmacies, and other stakeholders within the pharmaceutical supply chain. The company’s transactions typically involve direct sales of its innovative drug formulations to healthcare providers and retail pharmacies, facilitating access to its products for end-users. The revenue model encompasses various transaction structures, including B2B agreements with distributors and potential collaborations with healthcare organizations. Specific pricing plans and details regarding flagship products are aligned with the company's focus on ensuring competitive market positioning while maintaining high standards of safety and efficacy. The company is focused on designing and launching new products that meet the evolving needs of healthcare providers and patients. Additionally, New Haven Pharmaceuticals aims to expand into new markets, particularly within Europe, by 2025, ensuring that its innovative drug formulations are accessible to a broader audience. This strategic approach is expected to significantly enhance the company's market presence and impact within the pharmaceutical industry.
Who invested in New Haven Pharmaceuticals
4 investors across 2 rounds
See all investors in New Haven Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about New Haven Pharmaceuticals
Who invested in New Haven Pharmaceuticals?
New Haven Pharmaceuticals has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has New Haven Pharmaceuticals raised?
New Haven Pharmaceuticals has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did New Haven Pharmaceuticals last raise money?
New Haven Pharmaceuticals's most recent round on record is a Series B, in Oct 2014.
What does New Haven Pharmaceuticals do?
New Haven Pharmaceuticals is a pharmaceuticals company.
Where is New Haven Pharmaceuticals headquartered?
New Haven Pharmaceuticals is headquartered in Guilford, US.
Which VCs invest in companies like New Haven Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at New Haven Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like New Haven Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.